Here you can find out about some of the latest happenings

AbstractMixed-lineage leukemia 1 (MLL1) is a transcription activator of the HOX family, which binds to specific epigenetic marks on histone H3 through its third plant homeodomain (PHD3) domain. Through an unknown mechanism, MLL1 activity is repressed by cyclophilin 33 (Cyp33), which binds to MLL1 PHD3. We determined solution structures of Cyp33 RNA recognition motif (RRM) free, bound to RNA, to MLL1 PHD3, and to both MLL1 and the histone H3 lysine N6-trimethylated. We found that a conserved α helix, amino-terminal to the RRM domain, adopts three different positions facilitating a cascade of binding events. These conformational changes are triggered by Cyp33 RNA binding and ultimately lead to MLL1 release from the histone mark. Together, our mechanistic findings rationalize how Cyp33 binding to MLL1 can switch chromatin to a transcriptional repressive state triggered by RNA binding as a negative feedback loop.INTRODUCTIONCyclophilin 33 (Cyp33) is a 33-kDa protein with a C-terminal cycl

AbstractThe remarkable power of enzymes to undertake catalysis frequently stems from their grouping of multiple, complementary chemical units within close proximity around the enzyme active site. Motivated by this, we report here a bioinspired surfactant catalyst that incorporates a variety of chemical functionalities common to hydrolytic enzymes. The textbook hydrolase active site, the catalytic triad, is modeled by positioning the three groups of the triad (-OH, -imidazole, and -CO2H) on a single, trifunctional surfactant molecule. To support this, we recreate the hydrogen bond donating arrangement of the oxyanion hole by imparting surfactant functionality to a guanidinium headgroup. Self-assembly of these amphiphiles in solution drives the collection of functional headgroups into close proximity around a hydrophobic nano-environment, affording hydrolysis of a model ester at rates that challenge α-chymotrypsin. Structural assessment via NMR and XRD, paired with MD simulation and QM

It is said that Bonovi Biotech is an innovative biological enterprise with independent intellectual property rights integrating the research and development, production and sales of bioactive protease products. The company has a complete enzyme product development technology system and platform; Most of the products developed are more cutting-edge protease products at home and abroad, and the technical level is in the international advanced and domestic leading position.The company has an excellent R&D team, management team and first-class expert consultant team composed of doctors, masters, professors, researchers, senior engineers and other professionals. And with Peking University, Chinese Academy of Sciences, Chinese Academy of Agricultural Sciences and other domestic research institutes to establish a good cooperative relationship. While insisting on focusing on the R&D and production of proteases, Bionovat Biotech actively carries out business expansion and industrializat

name: alpha-chymotrypsin from bovine pancreasCAS：9004-07-3EINECS：232-671-2Chemical propertiesIt is used for the enzymatic hydrolysis of peptide chains, specializing in hydrolysis of peptide bonds, which belongs to peptide endonucleases and has a high hydrolysis yield.Specificity: Tyr-X, Trp-X, Phe-X (x<>Pro), but its specificity is less than that of trypsinSecurity terminologyS22Do not breathe dust.S24Avoid contact with skin.S26In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.S36/37Wear suitable protective clothing and gloves.Risk terminologyThis product is a proteolytic enzyme secreted by the pancreas, which can quickly decompose denatured proteins, and its function and use are similar to trypsin, with stronger decomposition ability, lower toxicity and less adverse reactions than trypsin. It thins viscous sputum and facilitates coughing up, and is effective for both purulent and non-purulent sputum. It is also used for wound healin

It is said that Bonovi Biotech is an innovative biological enterprise with independent intellectual property rights integrating the research and development, production and sales of bioactive protease products. The company has a complete enzyme product development technology system and platform; Most of the products developed are more cutting-edge protease products at home and abroad, and the technical level is in the international advanced and domestic leading position.The company has an excellent R&D team, management team and first-class expert consultant team composed of doctors, masters, professors, researchers, senior engineers and other professionals. And with Peking University, Chinese Academy of Sciences, Chinese Academy of Agricultural Sciences and other domestic research institutes to establish a good cooperative relationship. While insisting on focusing on the R&D and production of proteases, Bionovat Biotech actively carries out business expansion and industrializat

It is said that Bonovi Biotech is an innovative biological enterprise with independent intellectual property rights integrating the research and development, production and sales of bioactive protease products. The company has a complete enzyme product development technology system and platform; Most of the products developed are more cutting-edge protease products at home and abroad, and the technical level is in the international advanced and domestic leading position.The company has an excellent R&D team, management team and first-class expert consultant team composed of doctors, masters, professors, researchers, senior engineers and other professionals. And with Peking University, Chinese Academy of Sciences, Chinese Academy of Agricultural Sciences and other domestic research institutes to establish a good cooperative relationship. While insisting on focusing on the R&D and production of proteases, Bionovat Biotech actively carries out business expansion and industrializat

In a world first, the UK medicines regulator has approved a therapy that uses the CRISPR–Cas9 gene-editing tool as a treatment. The decision marks another high point for a biotechnology that has been lauded as revolutionary in the decade since its discovery.The therapy, called Casgevy, will treat the blood conditions sickle-cell disease and β-thalassaemia. Sickle-cell disease, also known as sickle-cell anaemia, can cause debilitating pain, and people with β-thalassaemia often require regular blood transfusions.“This is a landmark approval which opens the door for further applications of CRISPR therapies in the future for the potential cure of many genetic diseases,” said Kay Davies, a geneticist at the University of Oxford, UK, in comments to the UK Science Media Centre (SMC).Nature explains the research behind the treatment and explores what’s next.What research led to the approval?The approval by the Medicines and Healthcare products Regulatory Agency (MHRA)

Doubts about work claiming that certain molecules actively quell inflammation in the body have intensified. Critics have doubled down on their objections with a recent paper, and Science has learned that although a university publicly exonerated one of the researchers involved of misconduct, it appears to have at one point reached a different conclusion.The furor surrounds pioneering work on lipids known as specialized proresolving mediators (SPMs), done by Brigham and Women’s Hospital biochemist Charles Serhan and his former postdoc Jesmond Dalli, a molecular pharmacologist now at Queen Mary University of London (QMUL). More than a dozen scientists who have analyzed SPM research by Dalli, Serhan, and others formally published a critique of the work in Nature Communications last week. The analysis, which appeared last year as a preprint, attacks the method used to detect SPMs in many papers for producing misleading results. The journal also posted a rebuttal